vorinostat [clinicaltrials_resource:a1fcfde6e0f51e840fb0ca7ffbd9079f]
intervention [clinicaltrials_vocabulary:intervention]
vorinostat [clinicaltrials_resource:a1fcfde6e0f51e840fb0ca7ffbd9079f]
Bio2RDF identifier
a1fcfde6e0f51e840fb0ca7ffbd9079f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:a1fcfde6e0f51e840fb0ca7ffbd9079f
arm group [clinicaltrials_vocabulary:arm-group]
intervention desc [clinicaltrials_vocabulary:intervention-desc]
400 mg orally (po) every day on days 1-14 of a 21 day cycle
intervention name [clinicaltrials_vocabulary:intervention-name]
vorinostat
other name [clinicaltrials_vocabulary:other-name]
suberoylanilide hydroxamic acid (SAHA)
identifier
clinicaltrials_resource:a1fcfde6e0f51e840fb0ca7ffbd9079f
title
vorinostat
@en
type
label
vorinostat [clinicaltrials_resource:a1fcfde6e0f51e840fb0ca7ffbd9079f]
@en